|
Efficacy of intravitreal dexamethasone implant in chronic central serous chorioretinopathy: A pilot study
Umesh C Behera1, Miloni Shah1, Anup Kelgaonkar1, Jyotiranjan Sahoo2, Raja Narayanan3, Srinivas R Sadda4
1 Retina Vitreous Service, Anant Bajaj Retina Institute, L V Prasad Eye Institute (Mithu Tulsi Chanrai Campus), Bhubaneswar, Odisha, India
2 Department of Community Medicine, Institute of Medical Sciences and SUM Hospital, Siksha ‘O’ Anusandhan Deemed to be University, Bhubaneswar, Odisha, India
3 Retina Vitreous Service, Anant Bajaj Retina Institute, L V Prasad Eye Institute (Kallam Anji Reddy Campus), Hyderabad, Telangana, India
4 Retina Vitreous Service, Doheny Eye Institute, University of California, Los Angeles, CA, United States
Correspondence Address:
Umesh C Behera
L V Prasad Eye Institute, Bhubaneswar - 751 024, Odisha
India
 Source of Support: None, Conflict of Interest: None
DOI: 10.4103/IJO.IJO_2523_22
|
|
In a prospective proof-of-concept study probing the role of para-inflammation in central serous chorioretinopathy (CSC) pathogenesis, eligible subjects with chronic CSC non-responsive to conventional treatment received a single dexamethasone (DEX) implant monotherapy. Six middle-aged males (mean age = 46.5 ± 10.8 years) with a mean disease duration of 4.5 ± 2.5 years, at the primary efficacy endpoint of six weeks, showed complete resolution of subretinal fluid (SRF) in four out of six eyes, significant reduction of SRF height (174 ± 86 μm to 22 ± 34 μm; P = 0.028) and central subfield thickness (347 ± 139 μm to 180 ± 47 μm; P = 0.003), indicating DEX as a promising treatment option for chronic CSC.
|
